Effectiveness of a shortened cycle of monoimmunotherapy in non-small cell lung cancer
- Authors: Artemieva E.V1, Moiseenko F.V1,2,3, Volkov N.M1, Egorenkov V.V1, Abduloeva N.K.1, Bogdanov A.A1, Zhabina A.S1,2, Levchenko N.V1, Moiseenko V.M1
-
Affiliations:
- Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
- N.N. Petrov National Medical Research Center of Oncology
- North-Western State Medical University n.a. I.I. Mechnikov
- Issue: Vol 28, No 7 (2021)
- Pages: 127-132
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313189
- DOI: https://doi.org/10.18565/pharmateca.2021.7.127-132
- ID: 313189
Cite item
Abstract
Full Text
About the authors
E. V Artemieva
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
Email: mukhina_ev@mail.ru
St. Petersburg, Russia
F. V Moiseenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. MechnikovSt. Petersburg, Russia
N. M Volkov
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
V. V Egorenkov
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
N. Kh Abduloeva
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
A. A Bogdanov
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
A. S Zhabina
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological); N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. V Levchenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
V. M Moiseenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)St. Petersburg, Russia
References
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. First published: 08 January 2020. doi: 10.3322/caac.21590.
- URL: https://rosoncoweb.ru/standarts/ RUSSCO/2020/2020-02.pdf 3. URL: http://www.oncology.ru/association/
- URL: http://www.oncology.ru/association/ clinicalguidelines/2018/rak_legkogo_pr2018.pdf
- Zappa C., Mousa S.A. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi: 10.21037/tlcr.2016.06.07.
- Detterbeck F.C., Postmus P.E., Tanoue L.T. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):191- 210. doi: 10.1378/chest.12-2354
- Mayor M., Yang N., Sterman D., Jones D.R., Adusumilli P.S. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg. 2016;49(5):1324-33. doi: 10.1093/ejcts/ezv371.
- Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl.J Med. 2015;373:1627-39. Doi: 10.1056/ NEJMoa1507643.
- Waterhouse D.M., Garon E.B., Chandler J., et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced NonSmall-Cell Lung Cancer: CheckMate 153. doi: 10.1200/JC0.20.00131. Published: 2020-1120. Update policy: https://doi.org/10.1200/ CROSSMARK
- Borghaei H., Gettinger S., Vokes E.E., et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nlvolumab Versus Docetaxel in Previously Treated Non -Small-Cell Lung Cancer Accepted on November 5, 2020 and published at ascopubs.org/journal/ jco on January 15, 2021. Doi https://doi. org/ 10.1200/JC.
- Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohisto-chemistry: could it be predictive and/or prognostic in non-small cell lung cancer. Cancer Biol. Med. 2016;13:157-70. doi: 10.20892/j.issn.2095-3941.2016.0009.
- Brahmer J.R., Rodriguez-Abreu D., Robinson A.G., et al. KEYNOTE-024 5-year OS update: First-line pembrolizumab vs platinum-based chemotherapy in patients with metastatic NSCLC and PD-L1 tumour proportion score (TPS)>50%. ESMO 2020;abstract LBA51.
- Reck M., Rjdriguez-Abreu D., Robinson A.G., et al. Pembrolizumab versus chemothera-py for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33. Doi: 10.1056/ NEJMoa1606774.
- URL: https://recist.eortc.org/recist-1-1-2/
- URL: https://www.who.int/ru/director-general/ speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020